EC Number   |
Recommended Name  |
Application |
|---|
    1.3.5.1 | succinate dehydrogenase |
diagnostics |
mutations of SDH subunit encoding genes are good markers for paraganglioma |
| 1.3.5.1 | succinate dehydrogenase |
diagnostics |
SDHB mutations are a marker for a prognostic risk of patients with pheochromocytomas or paragangliomas |
| 1.3.5.1 | succinate dehydrogenase |
diagnostics |
succinate dehydrogenase subunits may be candidate susceptibility genes for some phosphatase and tensin homolog (PTEN, tumor suppressor) mutation-negative individuals with Cowden syndrome-like cancers. To address this hypothesis, germline succinate dehydrogenase subunits SDHB-D mutation analysis in 375 PTEN mutation-negative Cowden syndrome /Cowden syndrome -like individuals is performed, followed by functional analysis of identified SDH mutations/variants. Germline SDH mutations/variants occur in a subset of PTEN mutation-negative Cowden syndrome /Cowden syndrome -like individuals and are associated with increased frequencies of breast, thyroid, and renal cancers beyond those conferred by germline PTEN mutations. SDH testing should be considered for germline PTEN mutation-negative Cowden syndrome /Cowden syndrome -like -like individuals, especially in the setting of breast, thyroid, and/or renal cancers |
| 2.4.1.14 | sucrose-phosphate synthase |
diagnostics |
sucrose phosphate synthase gene SPS is a suitable endogenous reference gene for genetically modified rice detection, method development and validation of the SPS gene as an endogenous reference gene and its optimized qualitative and quantitative PCR systems, overview |
| 1.8.98.2 | sulfiredoxin |
diagnostics |
the lung cancer patients with high Srx levels have significantly shorter survival and those with high TXNDC5 levels have longer survival. Cellular levels of Srx and TXNDC5 may be useful as biomarkers to predict the survival of individuals with lung cancer |
| 1.15.1.1 | superoxide dismutase |
diagnostics |
Cu,Zn-SOD is a urinary marker of hepatic necrosis, but not hepatic fibrosis, overview |
| 1.15.1.1 | superoxide dismutase |
diagnostics |
the enzyme might be used to develop a biosensor for the detection of antioxidants and free radical activity |
| 1.15.1.1 | superoxide dismutase |
diagnostics |
Cu/Zn-SOD might be used as a bioindicator of the aquatic environmental pollution and cellular stress in pearl oyster |
| 1.15.1.1 | superoxide dismutase |
diagnostics |
the SOD in the cosmopolitan sponge Cliona celata is described as a useful biomarker for marine pollution in other marine invertebrates |
| 1.15.1.1 | superoxide dismutase |
diagnostics |
the variations of SOD expression pattern in yrtilus. edulis can be used as a tool for the marine environment monitoring |
| 3.4.21.68 | t-Plasminogen activator |
diagnostics |
alterations in tPA activity levels can be used as a biomarker for perturbations in brain homeostasis |
| 1.1.1.64 | testosterone 17beta-dehydrogenase (NADP+) |
diagnostics |
evaluation of 17beta-HSD3 enzymatic activity using androgen receptor-mediated transactivation is important for understanding and diagnosing the 46,XY disorder of sexual development caused by mutations of HSD17B3 genes which results in low testosterone production. A method is adapted that easily evaluates enzymatic activity of 17beta-HSD3 by quantifying the conversion from androstenedione to trestosterone using androgen receptor-mediated transactivation |
| 4.2.1.123 | tetrahymanol synthase |
diagnostics |
tetrahymanol is a polycyclic triterpenoid lipid in the Tetrahymena ciliates. The diagenetic product, gammacerane, is often used as a biomarker for water column stratification in ancient ecosystems |
| 3.4.24.27 | thermolysin |
diagnostics |
thermolysin is used in the diagnosis of prion diseases ovine scrapie and bovine spongiform encephalopathy, with similar sensitivity compared to proteinase K digestion, use of a protease to distinguish PrPC from PrPSc, overview |
| 1.8.3.2 | thiol oxidase |
diagnostics |
QSOX1 is a potential prognostic marker which may prove of use in the staging of breast tumours and the stratification of breast cancer patients |
| 1.8.3.2 | thiol oxidase |
diagnostics |
the expression of QSOX1 in neuroblastoma tumors may influence its clinical course because this protein is involved in processes such as the maturation of the extracellular matrix and the induction of apoptosis in these tumors. The enzyme can be used as a prognostic biomarker to help better discriminate among risk groups |
| 2.1.1.67 | thiopurine S-methyltransferase |
diagnostics |
the chip-based miniaturization provides a clinically feasible genotyping platform for one-at-a-time testing |
| 2.1.1.67 | thiopurine S-methyltransferase |
diagnostics |
thiopurine S-methyltransferase genotypes or phenotypes may be a predictive factor for azathioprine-induced toxicities |
| 6.1.1.3 | threonine-tRNA ligase |
diagnostics |
enzyme TARS is a regulator of the tumor microenvironment and possible target for diagnosis and/or treatment in ovarian cancer. The enzyme has a potential value as an ovarian cancer diagnostic |
| 3.4.21.5 | thrombin |
diagnostics |
concentrations of active alpha-thrombin, tissue factor-factor VIIa-factor Xa ternary complex, and intrinsic tenase complex with factor X, at specific time windows, can be used to classify acute coronary syndromes to an accuracy of about 87.2%. Such a combination can be used to efficiently assay the coagulation system |
| 2.7.1.21 | thymidine kinase |
diagnostics |
combined detection of the three tumor markers, serum alpha-L-fucosidase, alpha-fetoprotein and thymidine kinase 1 can play a complementary role in the diagnosis of hepatocellular carcinoma, and can significantly improve the sensitivity for the diagnosis of hepatocellular carcinoma |
| 2.7.1.21 | thymidine kinase |
diagnostics |
double immunostaining for thymidine kinase-1 (TK1)/CD31 can detect activated tumor vessels more accurately than staining for Ki67/CD31 and potentially could identify tumors that will respond to anti-angiogenic therapy |
| 2.7.1.21 | thymidine kinase |
diagnostics |
plasma thymidine kinase is a circulating prognostic marker in ER+//HER2- metastatic breast cancer patients treated with endocrine therapy and palbociclib |
| 2.7.1.21 | thymidine kinase |
diagnostics |
serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer |
| 1.3.1.20 | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase |
diagnostics |
overexpression of dihydrodiol dehydrogenase as a prognostic marker in resected gastric cancer patients, patients with DDH overexpression have a significantly higher incidence of early tumor recurrence and distant metastasis |
| 3.4.21.B21 | trepolisin |
diagnostics |
Treponema denticola chymotrypsin-like protease is associated with human papillomavirus-negative oropharyngeal squamous cell carcinoma |
| 3.6.1.2 | trimetaphosphatase |
diagnostics |
the enzyme is a cytochemical marker for lysosomes |
| 5.3.1.1 | triose-phosphate isomerase |
diagnostics |
triosephosphate isomerase is a serum marker for human lung squamous cell carcinoma |
| 3.4.14.9 | tripeptidyl-peptidase I |
diagnostics |
potential markers for Sjoegren's syndrome |
| 3.4.14.9 | tripeptidyl-peptidase I |
diagnostics |
saliva is a reliable and non-invasive source for the diagnosis of infantile (CLN1) and late infantile (CLN2) neuronal ceroid lipofuscinoses |
| 1.3.1.91 | tRNA-dihydrouridine20 synthase [NAD(P)+] |
diagnostics |
the enzyme defined as an independent prognostic factor for the development of non-small cell lung cancer cells |
| 1.14.16.2 | tyrosine 3-monooxygenase |
diagnostics |
tyrosine hydroxylase is frequently used as a marker of dopaminergic neuronal loss in animal models of Parkinsons disease |
| 3.4.21.73 | u-Plasminogen activator |
diagnostics |
expression level of uPA in prostate cancer tissue can be used as a predictor of biochemical recurrence in patients undergoing radical prostatectomy, i.e. strong expression of uPA in addition to a Gleason score, positive surgical margin, and lymph node metastasis |
| 3.4.21.73 | u-Plasminogen activator |
diagnostics |
uPA is the strongest single indicator of poor prognosis in patients with metastatic breast cancer |
| 3.4.21.73 | u-Plasminogen activator |
diagnostics |
urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer, overview |
| 3.4.19.12 | ubiquitinyl hydrolase 1 |
diagnostics |
ubiquitin C-terminal hydrolase is a biomarker in humans for severe traumatic brain injury |
| 3.4.19.12 | ubiquitinyl hydrolase 1 |
diagnostics |
UCH-L1 is a biomarker for ischemic and traumatic brain injury in rats |
| 3.4.19.12 | ubiquitinyl hydrolase 1 |
diagnostics |
UCH-L1 is a biomarker for lymph node metastasis in colorectal cancer |
| 3.4.19.12 | ubiquitinyl hydrolase 1 |
diagnostics |
UCHL1 is a potential cerebrospinal fluid biomarker of neuronal loss in aneurysmal subarachnoid hemorrhage and presumably other CNS damage and disease states, overview |
| 2.7.7.12 | UDP-glucose-hexose-1-phosphate uridylyltransferase |
diagnostics |
the enzyme activity is measured for determination of galactosaemia using erythrocyte from blood samples, HPLC-based method development, overview |
| 1.1.1.336 | UDP-N-acetyl-D-mannosamine dehydrogenase |
diagnostics |
the wecC gene may represent a useful method for detecting the human type of Edwardsiella tarda, which may have the ability to cause human infection |
| 2.7.4.14 | UMP/CMP kinase |
diagnostics |
UMP-CMP kinase (CMPK1) as a prognostic marker for triple negative breast cancer. Analysis of 461 breast adenocarcinoma samples, overview. While cytoplasmic CMPK1 does not show any association to metastasis free survival (MFS), nuclear CMPK1 is associated to poor prognosis independently from other prognostic factors in stratified Cox regression analyses |
| 6.3.4.6 | urea carboxylase |
diagnostics |
enzymatic assay for measurement of serum urea nitrogen using urea amidolyase |
| 2.4.2.3 | uridine phosphorylase |
diagnostics |
UPP1 may serve as a negative prognosticator in glioma, analysis of the prognostic value of UPP1 for glioma, overview. UPP1 predicts shorter survival for glioma |
| 2.4.2.3 | uridine phosphorylase |
diagnostics |
upregulation of UPP1 increases lymph node metastasis risk and is useful as diagnostic, prognostic, and predictive biomarker in thyroid cancer |
| 2.7.1.48 | uridine/cytidine kinase |
diagnostics |
prognostic significance of UCK2 gene in patients with breast cancer. UCK2 is required for chexadmosensitivity |
| 2.7.1.48 | uridine/cytidine kinase |
diagnostics |
increased UCK2 expression is an independent prognostic indicator of shorter overall survival and recurrence-free survival. UCK2 upregulation might serve as an indicator of unfavorable prognosis of hepatocellular carcinoma |
| 4.1.1.37 | uroporphyrinogen decarboxylase |
diagnostics |
uroporphyrinogen decarboxylase activity has a high diagnostic accuracy for differentiating the 2 Porphyria cutanea tarda types, the sporadic (sPCT) and familial (fPCT) forms, which are generally clinically indistinguishable, a model that takes into account both clinical information and laboratory test results can be used to predict fPCT |
| 1.3.8.9 | very-long-chain acyl-CoA dehydrogenase |
diagnostics |
maternal riboflavin deficiency in combination with decreased VLCAD activity can result in false-positive VLCADD neonatal screening results with multiple acyl-CoA dehydrogenase deficiency-like biochemistry |
| 2.3.1.297 | very-long-chain ceramide synthase |
diagnostics |
important role for the CerS genes in breast cancer etiology or diagnosis, overview |
| 3.4.13.9 | Xaa-Pro dipeptidase |
diagnostics |
cord blood prolidase activity may be a good indicator of fetal maturation and gestational age |
| 3.4.13.9 | Xaa-Pro dipeptidase |
diagnostics |
prolidase might be a useful marker for the diagnosis of lymphoma |
| 3.4.13.9 | Xaa-Pro dipeptidase |
diagnostics |
prolidase activity may be a useful adjunctive tool in predicting liver fibrosis, especially in the absence of advanced fibrosis and other conditions, which may affect the interpretation of prolidase activity |
| 3.4.13.9 | Xaa-Pro dipeptidase |
diagnostics |
prolidase is a marker of collagen turnover |
| 3.4.13.9 | Xaa-Pro dipeptidase |
diagnostics |
prolidase is a potential biomarker for melanoma, and the enzyme is a target for drug development in cancer therapy |
| 1.17.3.2 | xanthine oxidase |
diagnostics |
the enzyme activity detection in sepsis can be used for a negative prognosis in sepsis diagnosis, overview |
| 2.7.11.27 | [acetyl-CoA carboxylase] kinase |
diagnostics |
strong expression of phosphorylated acetyl-CoA carboxylase is an independent prognostic marker for patients with nodepositive of squamous cell carcinoma of the head and neck |
| 2.3.1.39 | [acyl-carrier-protein] S-malonyltransferase |
diagnostics |
coupled enzyme assay can be used in development and optimization of small-molecule inhibitors for antibacterial therapy |
| 2.8.2.30 | [heparan sulfate]-glucosamine 3-sulfotransferase 3 |
diagnostics |
heparan sulfate sulfotransferase 3-OST3A (HS3ST3A) is a tumor regulator and a prognostic marker in breast cancer HER2+ patients for reduced relapse-free survival |
| 2.8.2.30 | [heparan sulfate]-glucosamine 3-sulfotransferase 3 |
diagnostics |
specific HS sulfotransferases may serve as molecular markers and targets for cancer treatment |
| 2.8.2.8 | [heparan sulfate]-glucosamine N-sulfotransferase |
diagnostics |
NDST-2 expression is a late differentiation marker for mast cells |
| 2.8.2.B6 | [heparan sulfate]-iuronate 2-sulfotransferase |
diagnostics |
specific HS sulfotransferases may serve as molecular markers and targets for cancer treatment |
| 1.14.99.66 | [histone H3]-N6,N6-dimethyl-L-lysine4 FAD-dependent demethylase |
diagnostics |
dimethylation of histone H3 at lysine 4 in combination with trimethylation of histone H3 at lysine 4 is associated with an activated transcriptional state. An increase of H3K4diMe in neoplastic tissues is predictive of clinical outcome. In particular, tumor recurrence occurs earlier in low-grade prostate carcinoma patients with low H3K4diMe, independently of other clinical and pathologic parameters. Similarly, in large cell and squamous cell carcinomas, low H3K4diMe expression correlates with short survival |
| 1.16.1.8 | [methionine synthase] reductase |
diagnostics |
the MTRR A66G polymorphism is a potential biomarker for cancer risk |
